Ardelyx, Inc. (ARDX)
NASDAQ: ARDX · Real-Time Price · USD
3.000
-0.080 (-2.60%)
At close: Oct 26, 2026, 4:00 PM EDT
2.990
-0.010 (-0.33%)
After-hours: Oct 26, 2026, 7:55 PM EDT
Ardelyx Revenue
Ardelyx had revenue of $120.88M in the quarter ending June 30, 2026, with 23.77% growth. This brings the company's total for the last twelve months to $450.89M, up 16.77% year-over-year. In the year 2025, Ardelyx had annual revenue of $407.32M with 22.09% growth. That makes Ardelyx the 11,816th largest company in the world by revenue and 2,353rd in the United States.
Revenue (ttm)
$450.89M
Revenue Growth
+16.77%
P/S Ratio
1.66
Revenue / Employee
$922,074
Employees
489
Market Cap
747.56M
Revenue by Geography
- United States 377.81M 92.8%
- Asia Pacific 29.17M 7.2%
- North America 342.00K 0.1%
Fiscal year ended Dec 31, 2025 See the full Ardelyx breakdown
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 407.32M | 73.71M | 22.09% |
| Dec 31, 2024 | 333.62M | 209.16M | 168.06% |
| Dec 31, 2023 | 124.46M | 72.30M | 138.61% |
| Dec 31, 2022 | 52.16M | 42.06M | 416.57% |
| Dec 31, 2021 | 10.10M | 2.53M | 33.36% |
| Dec 31, 2020 | 7.57M | 2.29M | 43.36% |
| Dec 31, 2019 | 5.28M | 2.67M | 102.57% |
| Dec 31, 2018 | 2.61M | -39.39M | -93.79% |
| Dec 31, 2017 | 42.00M | - | - |
| Dec 31, 2016 | - | - | - |
| Dec 31, 2015 | 24.03M | -7.60M | -24.02% |
| Dec 31, 2014 | 31.62M | 2.70M | 9.32% |
| Dec 31, 2013 | 28.93M | 23.52M | 434.71% |
| Dec 31, 2012 | 5.41M | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. It does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| Pharming Group | 366.48M |
| Geron | 204.56M |
| Arbutus Biopharma | 181.72M |
| Apnimed | 115.12M |
| Kura Oncology | 77.23M |
| Inventiva | 2.81M |
ARDX News
- 3 days ago - Kaplan Fox Reminds Ardelyx, Inc. (ARDX) Investors to Seek a Leadership Role Before Deadline on November 16, 2026 - Newsfile Corp
- 3 days ago - Ardelyx Presents Real-World Data at ASN Kidney Week 2026 Showing Serum Phosphate Reductions Following XPHOZAH® (tenapanor) Initiation With or Without Phosphate Binders - GlobeNewsWire
- 5 days ago - Kaplan Fox Urges Ardelyx, Inc. (ARDX) Investors to Contact the Firm Before the Deadline on November 16, 2026 - Newsfile Corp
- 6 days ago - Ardelyx to Report Third Quarter 2026 Financial Results on November 3, 2026 - GlobeNewsWire
- 11 days ago - Kaplan Fox Encourages Ardelyx, Inc. (ARDX) Investors to Contact the Firm Before the Deadline on November 16, 2026 for a Leadership Role - Newsfile Corp
- 12 days ago - ARDX Stockholders Have Rights - If You Lost Money Investing in Ardelyx, Inc. Contact Robbins LLP for Information About Recovering Your Losses - PRNewsWire
- 13 days ago - Kaplan Fox Advises Ardelyx, Inc. (ARDX) Investors to Act Before the Lead Plaintiff Deadline on November 16, 2026 - Newsfile Corp
- 21 days ago - Ardelyx to Present New Data on Hyperphosphatemia Management at ASN Kidney Week 2026 - GlobeNewsWire